Ernexa Therapeutics Inc. (ERNA)
- Sector
- Healthcare
- Industry
- Biotechnology
- Last price
- $2.11
- As of
Kresmion compiles this page from ERNA's SEC filings, its 13F institutional holders and the market events Kresmion detects, each linked to its source.
Ernexa Therapeutics Inc. (ERNA): 1 institutional manager tracked by Kresmion reported non-option positions in their 2026Q2 Form 13F filings, and the most recent SEC filing on record for the company is a Form 8-K filed 2026-09-16.
See the full ERNA dossier
Price with insider and filing markers, who is positioning, fundamentals and peers for ERNA on one page. Preview it with sample data, then open it live with a free account.
Preview the ERNA dossierActive signals for ERNA
- mediumNEW_POSITION
CITADEL ADVISORS LLC new position in ERNA
- mediumEARNINGS_MISS
Q1-2022: Missed consensus by 19.0% - EPS $-1275 vs $-1071 estimate
- mediumEARNINGS_BEAT
Q2-2022: Beat consensus by 54.8% - EPS $-450 vs $-994.5 estimate
- mediumEARNINGS_MISS
Q3-2022: Missed consensus by 11.0% - EPS $-933.75 vs $-841.5 estimate
- mediumEARNINGS_MISS
Missed consensus by 19.0% - EPS $-1275 vs $-1071 estimate
FREE, NO ACCOUNT
Every signal on ERNA, as it fires
You are seeing 5 of 7 signals recorded on ERNA since 2026-05-30.
The five above landed across 3 days. The other 2 were recorded on those same days.
No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.
Largest reported share positions in ERNA (2026Q2)
| Manager / security | Market value | % portfolio | QoQ |
|---|---|---|---|
| CITADEL ADVISORS LLCCUSIP 114082407 · 2026Q2 | $100K | 0.00% | , |
Quarterly SEC Form 13F disclosures from the managers Kresmion tracks, not a complete ownership ranking. Non-option holdings only; reported put and call positions are excluded. Different securities are labeled by CUSIP. Values are reporting-period snapshots, not current position values. Filings can arrive up to 45 days after quarter-end.
Recent SEC filings, ERNA
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-KSEC EDGAR ↗
ERNA against its peers
ERNA's operating margin of -1601.2% ranks in the 56th percentile of 7 Biotechnology sub-industry peers, fiscal periods ending between 2025-12-31 and 2026-06-30.
| Metric | ERNA | Peer median | Percentile | n |
|---|---|---|---|---|
| Revenue FY | 582000 USD | 54232 USD | 55 | 9 |
| Gross margin | 83.5% | 77.6% | 75 | 5 |
| Operating margin | -1601.2% | -2190.0% | 56 | 7 |
| Net margin | -2419.9% | -1721.0% | 44 | 7 |
| Return on equity | -586.6% | -120.7% | 3 | 15 |
| 1 year | -93.5% | -88.1% | 35 | 12 |
Peers (19): GRI, PMCB, PCSA, EMMA, APTOF, CLDI, NCNA, HCWB, MBIO, ONCO, CVKD, GLMD, SXTP, APVO, REVB, XBIO, LNAI, JUNS, KAPA. Left out: ENLV (no annual filing), BVAXF (no annual filing), MLEC (period gap), LIMN (no annual filing), XTLB (period gap), XRTX (no annual filing). Fiscal periods ending between 2025-12-31 and 2026-06-30. Every figure is one full fiscal year read from one annual filing (ERNA: 10-K), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.
Related tickers
Follow ERNA on a live board
Kresmion is a cross-asset market-intelligence terminal. Open a board scoped to ERNA for its filings, 13F changes, insider trades, options positioning, and confluence read in one view, each with its source.